Stock-based Compensation

3 Months Ended

Mar. 31, 2020

(11) Stock-based Compensation

Stock-based compensation expense related to stock options issued under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan (the “Plan”) and as inducement grants for the three months ended March 31, 2020 and 2019 was as follows:


	Three Months Ended
	March 31,
	2020		2019
Selling and marketing	$	—	$	77
General and administrative		427		1,146
Research and development		—		33
Total	$	427	$	1,256

As of March 31, 2020 there was approximately $1.1 million of total unrecognized compensation costs related to unvested stock option awards, which are to be recognized over a weighted-average period of 1.9 years. There were no stock options granted during both the three months ended March 31, 2020 and 2019.